The FirstGene Multiple Prenatal Screen provides a streamlined option to bring together key insights with a single blood sample.
Assesses the carrier status of the pregnant individual for 11 recessive conditions with a >99% sensitivity and specificity.1
Fetal Aneuploidy Screen Assesses fetal risk for aneuploidies without screening of the reproductive partner. Screen includes:
Assesses fetal risk for the inheritance of 10 common, actionable conditions with a >98% detection for the majority of conditions across all ancestries.1 No paternal sample needed.
Assesses RhD compatibility between the pregnant person and the fetus with 100% sensitivity and specificity for copy number variant calling.1
FirstGene delivers actionable genetic insights with a simple blood draw from your pregnant patient as early as 10 weeks gestation. No need for paternal screening. So you can support your patients with actionable insights, faster.
FirstGene brings it all together. One screen. One sample. One clear, cohesive report. Everything you need including patient carrier screening, fetal aneuploidy screening, fetal recessive disease screening, and RhD compatibility screening. All delivered in a single, integrated format designed to streamline your workflow and support faster, more comprehensive care.
Are you a prenatal care provider who offers carrier screening and pcfDNA? We’re looking to collaborate with clinical sites that offer these services. Through this study, you can help evaluate the impact of the FirstGene screen and bring more insights to prenatal care.
Contact Information
See the research and explore how the FirstGene screen is changing prenatal screening.
eposter #1914
Comprehensive prenatal cfDNA screening via simultaneous assessment of aneuploidy, single-gene conditions, and fetomaternal blood compatibility
Poster ID # PRE351
Validation of Fetal RHD Copy Number Calling in FirstGene, a Combined Non-Invasive Prenatal cfDNA Assay for Fetal Aneuploidy, Recessive Diseases, and Serological Screening
Poster ID # 7047T
Validation of Fetal and Maternal Spinal Muscular Atrophy (SMA) and Hemoglobin (Hb) Bart’s Screening with FirstGene, a Combined Non-Invasive Prenatal cfDNA Assay for Fetal Aneuploidy, Recessive Diseases, and Serological Screening
Poster ID # PRE348
Validation of Fetal Aneuploidy Detection with FirstGene: a Combined, Non-Invasive Prenatal cfDNA Assay for Fetal Aneuploidy, Recessive Diseases, and Serological Screening
Our board-certified genetic counselors are available to support both you and your patients after results are delivered.
Myriad will send a personalized cost estimate for each patient directly via email or text.
Knowledge early on means timely care and more options, and increased assurance in the decisions that matter most.